A61P 21 - Drugs for disorders of the muscular or neuromuscular system

Patents for A61P 21 - Drugs for disorders of the muscular or neuromuscular system (23,287)
12/2001
12/06/2001	CA2410453A1 Neuroprotective peptides
12/06/2001	CA2410084A1 Transporters and ion channels
12/06/2001	CA2409311A1 Regulators of apoptosis
12/05/2001	EP1160318A2 Medicament for treatment of Duchenne muscular dystrophy
12/05/2001	EP1160254A1 Human vanilloid receptor-like proteins
12/05/2001	EP1159457A1 T cell receptor vbeta beta-jbeta) sequence and methods for its detection
12/05/2001	EP1159405A2 Viral particles which are released after the infection with the human cytomegalovirus and the use of said particles as a vaccine
12/05/2001	EP1159288A1 Alpha-conotoxin peptides
12/05/2001	EP1159284A1 33 human secreted proteins
12/05/2001	EP1159262A1 Tyrosine alkoxyguanidines as integrin inhibitors
12/05/2001	EP1159006A2 Water-soluble compositions of bioactive lipophilic compounds
12/05/2001	EP1158996A1 Novel amide derivatives as growth hormone secretagogues
12/05/2001	EP0971880B1 Solid compositions suitable for oral administration comprising non hygroscopic salts of l-carnitine and alkanoyl-l-carnitine with 2-aminoethanesulfonic acid
12/05/2001	CN1325408A Compounds with growth hormone releasing propenties
12/05/2001	CN1325303A Tocopherols, tocotrienols, other chroman and side chain derivatives and uses
12/04/2001	US6326507 Therapeutic compounds and methods of use
12/04/2001	US6326385 Administering poltassium channel modulator
11/2001
11/29/2001	WO2001090334A2 Drug metabolizing enzymes
11/29/2001	WO2001090148A2 Neurotransmitter transporters
11/29/2001	WO2001090110A1 Macrolides
11/29/2001	WO2001090086A1 A polymorph of 5-(4-aminosulfonyl-3-fluorophenyl)-4-cyclohexyl-2-methyloxazole
11/29/2001	WO2001090082A1 Substituted 1-aminoalkyl-lactams and their use as muscarinic receptor antagonists
11/29/2001	WO2001090081A1 Substituted 1-aminoalkyl-lactams and their use as muscarinic receptor antagonists
11/29/2001	WO2001090076A1 Fluoroalkoxy-substituted benzamide dichloropyridinyl n-oxide pde4 inhibitor
11/29/2001	WO2001090070A2 Caspase inhibitors and uses thereof
11/29/2001	WO2001090063A2 Prodrug of an ice inhibitor
11/29/2001	WO2001089570A2 Combination of growth hormone secretagogues and antidepressants
11/29/2001	WO2001089568A1 Nrg-2 nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods
11/29/2001	WO2001089543A2 Use of proanthocyanidins as an active ingredient of a stimulator and l-arginine or its salts as a source of nitric oxide to relieve symptoms of erectile dysfuntion
11/29/2001	WO2001089537A2 Apoptotic entities for use in treatment of neurodegenerative and other neurological disorders
11/29/2001	WO2001089521A1 Medicinal compositions containing thiophene derivatives
11/29/2001	WO2001089520A2 Dehydroascorbic acid formulations and uses thereof
11/29/2001	WO2001089451A2 Protease inhibitors
11/29/2001	WO2001089450A2 Treating musculoskeletal disorders using lp85 and analogs thereof
11/29/2001	WO2001070695A8 Pyridine derivatives as inhibitors of p38
11/29/2001	US20010047031 Heterocyclic compounds useful as NMDA receptor selective subtype blockers
11/29/2001	US20010047014 4-Benzyl-1-(2-(p-hydroxyphenoxy)ethyl)piperidine-3,4-diol; preparation from 1-(2-haloethoxy)-4-benzyloxybenzene and 4-benzylpiperidine-3,4-diol
11/29/2001	US20010047011 Preventing and treating motor neuron diseases such as ALS
11/29/2001	US20010046993 5-memberd heteroaryl substituted 1,4-dihydropyridine compounds as bradykinin antagonists
11/29/2001	US20010046988 Especially treating fibromyalgia, chronic fatigue syndrome, psychogenic pain and chromic pain
11/29/2001	US20010046962 Presynaptic neurotoxin such as botulinum toxin A
11/29/2001	US20010046490 Cell surface molecule-induced macrophage activation
11/29/2001	CA2808215A1 Nrg-2 nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods
11/29/2001	CA2429199A1 Drug metabolizing enzymes
11/29/2001	CA2408562A1 Dehydroascorbic acid formulations and uses thereof
11/29/2001	CA2408141A1 Neurotransmitter transporters
11/29/2001	CA2408036A1 Combination of growth hormone secretagogues and antidepressants
11/29/2001	CA2407780A1 Fluoroalkoxy-substituted benzamide dichloropyridinyl n-oxide pde4 inhibitor
11/29/2001	CA2406829A1 Protease inhibitors
11/29/2001	CA2380935A1 Caspase inhibitors and uses thereof
11/28/2001	EP1157992A1 Dihydro-2,3-Benzodiazepine derivatives
11/28/2001	EP1157022A1 Pyridine compounds and their pharmaceutical use
11/28/2001	EP1157003A1 Acylated aminoacetonitriles as cysteine protease inhibitors
11/28/2001	CN1324353A Amidine derivatives, their preparation and application as medicines and pharmaceutical compositions containing same
11/28/2001	CN1324352A 2-phenylpyran-4-one derivatives
11/28/2001	CN1324251A Method of stimulating prosaposin receptor activity
11/28/2001	CN1324236A Delta 9 tetrahydrocannabinol (delta 9 THC) solution metered dose inhalers and methods of use
11/27/2001	US6323208 Compounds to treat neurodegenerative, psychotropic drug and alcohol induced central and induced central and peripheral nervous system disorders.
11/27/2001	US6322806 Over-coated chewing gum formulations including tableted center
11/25/2001	CA2309424A1 Apoptotic entities for use in treatment of neurodegenerative and other neurological disorders
11/22/2001	WO2001088134A2 Novel human lipocalin homologs and polynucleotides encoding the same
11/22/2001	WO2001088108A1 Neuronal serine-threonine protein kinase
11/22/2001	WO2001087870A1 Hydroxamic acid derivatives
11/22/2001	WO2001087849A2 Modulators of tnf- alpha signaling
11/22/2001	WO2001087376A1 Drug/drug delivery systems for the prevention and treatment of vascular disease
11/22/2001	WO2001087374A1 Delivery systems for treatment of vascular disease
11/22/2001	WO2001087373A1 Delivery devices for treatment of vascular disease
11/22/2001	WO2001087343A2 Combination therapy using cox-2 selective inhibitor and thromboxane inhibitor and compositions therefor
11/22/2001	WO2001087342A2 Delivery devices for treatment of vascular disease
11/22/2001	WO2001087338A1 Immunomodulatory human mhc class ii antigen-binding polypeptides
11/22/2001	WO2001087337A1 Human polypeptides causing or leading to the killing of cells including lymphoid tumor cells
11/22/2001	WO2001087308A1 Treatment of fibromyalgia and chronic fatigue syndrome
11/22/2001	WO2001087267A1 Protein matrix materials, devices and methods of making and using thereof
11/22/2001	WO2001087263A2 Delivery systems for treatment of vascular disease
11/22/2001	WO2001035995A3 Tr3-specific binding agents and methods for their use
11/22/2001	US20010044459 Hydroxamic acid derivatives
11/22/2001	US20010044448 Prevention/treatment of motor neuron diseases; amyotrophic lateral sclerosis
11/22/2001	US20010044428 Aminopyridines and methods of using thereof
11/22/2001	US20010044122 Enriched central nervous system stem cell and progenitor cell populations, and methods for identifying, isolating and enriching for such populations
11/22/2001	US20010042936 Process for producing solid creatine dosage forms and dosage forms obtainable thereby
11/22/2001	CA2781858A1 Modulators of tnf-.alpha. signaling
11/22/2001	CA2409035A1 Hydroxamic acid derivatives
11/22/2001	CA2408827A1 Novel human lipocalin homologs and polynucleotides encoding the same
11/22/2001	CA2408729A1 Delivery systems for treatment of vascular disease
11/22/2001	CA2408719A1 Antiproliferative drug and delivery device
11/22/2001	CA2408608A1 Antiinflammatory drug and delivery device
11/22/2001	CA2408513A1 Immunomodulatory human mhc class ii antigen-binding polypeptides
11/22/2001	CA2408408A1 Modulators of tnf- alpha signaling
11/22/2001	CA2408360A1 Human polypeptides causing or leading to the killing of cells including lymphoid tumor cells
11/22/2001	CA2407469A1 Combination therapy using cox-2 selective inhibitor and thromboxane inhibitor and compositions therefor
11/22/2001	CA2404704A1 Treatment of fibromyalgia and chronic fatigue syndrome
11/21/2001	EP1155693A1 Intermittent claudication remedies
11/21/2001	EP1155304A2 A system for cell-based screening
11/21/2001	EP1155014A1 New benzimidazole compounds for use as active therapeutic substances, process for the preparation of these compoudns and pharmaceutical compositions comprising them
11/21/2001	EP1154988A1 Mevinolin derivatives
11/21/2001	EP1154801A1 Integration of transplanted neural progenitor cells into neural tissue of immature and mature dystrophic recipients
11/20/2001	US6319944 Nmda nr2b antagonists; neurological and neurodegenerative diseases including pain, (and in particular neuropathic pain), epilepsy, stroke, anxiety, cerebral ischemia, muscular spasms, alzheimer's, huntington's and parkinson's diseases
11/15/2001	WO2001085980A2 Enzymatic assays for screening anti-cancer agents
11/15/2001	WO2001085942A2 Cytoskeleton-associated proteins
11/15/2001	WO2001085781A2 Repair of nerve damage

1 ... 182 183 184 185 186 187 188 189 190 191 192 193 194 195 196 197 198 199 200 201 202 ... 233